Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000196044
Ethics application status
Not yet submitted
Date submitted
5/03/2010
Date registered
8/03/2010
Date last updated
8/03/2010
Type of registration
Prospectively registered
Titles & IDs
Public title
Effect of obesity and diabetes on treatment and outcomes in newly diagnosed breast cancer
Query!
Scientific title
A prospective study to investigate the total body exposure to chemetherapeutic drugs in node positive breast cancer patients classified by obesity and diabetes subgroups
Query!
Secondary ID [1]
1465
0
None
Query!
Universal Trial Number (UTN)
None
Query!
Trial acronym
None
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast cancer chemotherapy dosing
256914
0
Query!
Condition category
Condition code
Cancer
257062
257062
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
A 1 year prospective study of node positive breast cancer patients presenting to the Princess Alexandra Hospital will be undertaken to examine total body exposure of chemotherapy drugs. Baseline data on obesity , diabetes and other factors that may influence drug exposure including weight and height at diagnosis; basic biochemistry including glucose, diabetes diagnosis and control; stage of disease; co-morbidities (such as renal impairment); use of hormone replacement therapy, medications, dose and type of chemotherapy will be collected. Total body exposure for the various chemotherapeutic agents used will be calculated by measuring serum drug levels at various points in time points ( 0 hrs,1 hr, 2hrs, 4hrs and 8 hours) during administration of these drugs during the first cylcle of chemotherapy.
Results: The total body exposure will be analysed to see if their is a statistical difference in the different obesity and diabetes groupings. We will look at both the relative under-dosing in obese women with breast cancer, and the combined effect of diabetes and obesity on other known risk factors for breast cancer. Ultimately if it can be clearly shown that obesity results in less than optimal chemotherapy treatment and may result in reduced survival, then treatment of obesity and good diabetes control may become an even more important facet of breast cancer management. This is particularly pertinent given our epidemic of obesity and of diabetes.
Query!
Intervention code [1]
256110
0
Not applicable
Query!
Comparator / control treatment
n/a
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
257952
0
Establishing whether adequate total body exposure to the chemotherapeuting agent has been achieved inthe various subgroups by calculated area under the curve for chemotherapy drugs
Query!
Assessment method [1]
257952
0
Query!
Timepoint [1]
257952
0
1 year from the start of the study. This is expected to be the time period to recruit ther equired number of participants
Query!
Primary outcome [2]
257953
0
survival will be done as part of another study 10 years down the track by linking these patients with the National cancer registry
Query!
Assessment method [2]
257953
0
Query!
Timepoint [2]
257953
0
10 years from the time of recruitment
Query!
Secondary outcome [1]
263480
0
mortality will be done as part of another study 10 years down the track by linking these patients with the National cancer registry
Query!
Assessment method [1]
263480
0
Query!
Timepoint [1]
263480
0
10 year from the time of recruitment
Query!
Eligibility
Key inclusion criteria
node positive breast cancer
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
pregnancy, <18 years
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/05/2010
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
128
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
256605
0
Self funded/Unfunded
Query!
Name [1]
256605
0
Query!
Address [1]
256605
0
Query!
Country [1]
256605
0
Query!
Primary sponsor type
University
Query!
Name
University of Queensland
Query!
Address
Level 4 ;School of medicine
Princess Alexandra Hospital
qld 4102
Query!
Country
Australia
Query!
Secondary sponsor category [1]
255897
0
Hospital
Query!
Name [1]
255897
0
Princess Alexandra Hospital
Query!
Address [1]
255897
0
Ipswich Road
Woolongabba
Qld 4102
Query!
Country [1]
255897
0
Australia
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
258633
0
Princess Alexandra Hospital Ethics commitee
Query!
Ethics committee address [1]
258633
0
Ipswich Road Woolongabba Qld 4102
Query!
Ethics committee country [1]
258633
0
Australia
Query!
Date submitted for ethics approval [1]
258633
0
15/03/2010
Query!
Approval date [1]
258633
0
Query!
Ethics approval number [1]
258633
0
Query!
Summary
Brief summary
Background: Obesity, type 2 diabetes and breast cancer are common diseases. Each of these alone are major health care problems in developed countries such as Australia. As more people acquire these diseases as they get older and as life expectancy increases, the health care costs of these will increase exponentially. Both obesity and diabetes, on its own can cause cancer. A recent study from Queensland and one other reviewing all of the data on this area suggested that both diabetes and obesity can increase death from breast cancer. There is a suggestion that some of this increased death rate may be because obese people and those with diabetes have other medical problems which may lead to reduced dose of chemotherapy being given. For these reasons it is a developing yet urgent area of research interest for patients, clinicians, Governments and policy makers. Aims: To Examine 1) whether obese women with breast cancer are more or less likely to be dosed with appropriate doses of chemotherapy 2) Whether there is a difference in total body exposure for the various chemotherapeutic agents utilised amongst the subgroups classified by obesity and diabetes. Method: A 1 year prospective study of node positive breast cancer patients presenting to the Princess Alexandra Hospital (PAH) will be undertaken to examine total body exposure of chemotherapy drugs. Baseline data on obesity , diabetes and other factors that may influence drug exposure including weight and height at diagnosis; basic biochemistry including glucose, diabetes diagnosis and control; stage of disease; co-morbidities (such as renal impairment); use of hormone replacement therapy, medications, dose and type of chemotherapy will be collected. Total body exposure for the various chemotherapeutic agents used will be calculated by measuring serum drug levels at various points in time points ( 0 hrs,1 hr, 2hrs, 4hrs and 8 hours) during administration of these drugs during the first cylcle of chemotherapy. Results: The total body exposure will be analysed to see if their is a statistical difference in the different obesity and diabetes groupings. We will look at both the relative under-dosing in obese women with breast cancer, and the combined effect of diabetes and obesity on other known risk factors for breast cancer. Ultimately if it can be clearly shown that obesity results in less than optimal chemotherapy treatment and may result in reduced survival, then treatment of obesity and good diabetes control may become an even more important facet of breast cancer management. This is particularly pertinent given our epidemic of obesity and of diabetes.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
30901
0
Query!
Address
30901
0
Query!
Country
30901
0
Query!
Phone
30901
0
Query!
Fax
30901
0
Query!
Email
30901
0
Query!
Contact person for public queries
Name
14148
0
Mohamed Saleem
Query!
Address
14148
0
level 4
School of medicine; Southside
Princess Alexandra Hospital
Qld 4102
Query!
Country
14148
0
Australia
Query!
Phone
14148
0
+61 7 31763066
Query!
Fax
14148
0
+61 7 31763999
Query!
Email
14148
0
[email protected]
Query!
Contact person for scientific queries
Name
5076
0
Mohamed Saleem
Query!
Address
5076
0
level 4
School of medicine; Southside
Princess Alexandra Hospital
Qld 4102
Query!
Country
5076
0
Australia
Query!
Phone
5076
0
+61 7 31763066
Query!
Fax
5076
0
+61 7 31763066
Query!
Email
5076
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF